Angelman Syndrome (AS) is a genetic disorder caused by a mutation in an autosomal chromosome, usually the 15th chromosome. This mutation is caused by either the deletion or the disruption of a gene on the chromosome, resulting in the disruption of the normal neurological development of the individual.
Some of the common symptoms of Angelman Syndrome include developmental delays, intellectual disabilities, seizures, problems with movement and balance, speech and language impairment, and a happy demeanor. Individuals with AS usually have an unbalanced gait and have difficulties with fine motor skills. They may also have problems with feeding and sleeping, as well as hyperactivity and repetitive behaviors.
The cause of the mutation is not always known, but it usually occurs de novo (not inherited) in the affected individual. It is thought to be caused by either the deletion or disruption of the UBE3A gene, which is responsible for the normal development of the nervous system in humans. In addition, other genetic mutations, including mutations in the E6-AP gene, have been linked to AS.
The diagnosis of Angelman Syndrome is based on a combination of clinical, laboratory, and genetic tests. In some cases, a genetic test may be performed to confirm the diagnosis. Treatment of Angelman Syndrome is focused on managing the symptoms and addressing the individual's needs. This may include physical therapy, occupational therapy, speech and language therapy, and medications to control seizures and other symptoms.
In conclusion, Angelman Syndrome is a genetic disorder caused by a mutation in an autosomal chromosome, usually the 15th chromosome. The mutation is usually caused by either the deletion or disruption of a gene on the chromosome, resulting in the disruption of the normal neurological development of the individual. Diagnosis is based on a combination of clinical, laboratory, and genetic tests, while treatment focuses on managing the symptoms and addressing the individual's needs.